The SITC Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multidisciplinary panels of experts. They draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations on when and how to use immunotherapy to help improve outcomes for patients with cancer.
These CPGs offer a vital resource for the practicing oncology community. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure a fair, transparent and balanced process for creating the CPGs. Each CPG expert panel is comprised of a comprehensive mix of academic physicians and researchers, nurses, patients and patient advocates invited from institutions across the United States.
The guidelines are reviewed on an ongoing basis to account for newly available clinical trial data and FDA approvals.
The SITC CPG Mobile App is available to give on-the-go access to the guidelines.
Highlighting key information from SITC’s published guidelines, the SITC CPG Mobile App serves as a comprehensive, flexible resource, providing clinicians with evidence- and consensus-based recommendations for the optimal utilization of immunotherapy in cancer treatment.
Covering a range of topics, from biomarkers and therapy selection to quality of life and management of immune-related adverse events, cancer professionals can find important aspects of immunotherapy treatment as well as interactive tools and companion educational resources. Busy clinicians will find the SITC CPG Mobile App as the go-to resource on when and how to use immunotherapy to help improve outcomes for patients with cancer.
Key features of SITC’s CPG Mobile App include:
